Ask AI
ProCE Banner Series

Advancing Pharmacist Excellence in RRMM: Optimizing Bispecific Antibody Selection, Safety, and Patient Care

Bispecific antibodies are changing the way relapsed/refractory multiple myeloma is clinically managed. This live virtual symposium will provide pharmacists with evidence-based guidance and insights into the latest advances in the identification, prevention, and management of adverse events associated with bispecific antibody therapies.

  ACPE-P
Who Should Attend

This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals caring for patients with multiple myeloma.

All Events

Advancing Pharmacist Excellence in RRMM: Optimizing Bispecific Antibody Selection, Safety, and Patient Care

Upcoming Events

May

20

2026

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Topics

Multiple Myeloma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence to optimize the identification, monitoring, and management of adverse events in patients with relapsed/refractory multiple myeloma receiving treatment with bispecific antibodies. 

Target Audience
This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals caring for patients with multiple myeloma.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Recognize key toxicities such as cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, cytopenias, infections, and agent-specific effects, using current guideline-based tools and protocols.
  • Interpret clinical trial data and real-world evidence to differentiate bispecific antibodies by targets, dosing strategies, safety profiles, and administration nuances, facilitating optimal agent selection and sequencing in relapsed/refractory multiple myeloma.
  • Develop competence in multidisciplinary care coordination, including managing inpatient ramp-up and outpatient maintenance workflows, emergency department collaboration for AE emergencies, and adherence to mandated REMS requirements.
  • Build skills to effectively counsel patients and caregivers on therapy expectations, AE recognition and reporting, infection prevention, adherence, and navigate equitable access challenges, especially for underserved populations.

Accreditation

CE Accreditation

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-006-L01-P has been assigned to this live application-based activity (initial release date May 20, 2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by ProCE, LLC.

ProCE, LLC

Supporters

Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191